Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Prime Medicine Inc shares valued at $23,790 were purchased by Brudnick Richard on May 20 ’25. At $1.19 per share, Brudnick Richard acquired 20,000 shares. The insider’s holdings grew to 20,000 shares worth approximately $24600.0 following the completion of this transaction.
Also, LEE ANN L. purchased 100,000 shares, netting a total of over 113,000 in proceeds. Following the buying of shares at $1.13 each, the insider now holds 100,000 shares.
Before that, Reine Allan had added 125,000 shares to its account. In a trade valued at $147,150, the Chief Executive Officer bought Prime Medicine Inc shares for $1.18 each. Upon closing the transaction, the insider’s holdings increased to 125,000 shares, worth approximately $0.15 million.
As published in a research note from JP Morgan on May 20, 2025, Prime Medicine Inc [PRME] has been rated down from an Overweight to a Neutral. Analysts at H.C. Wainwright downgraded the stock from ‘”a Buy”‘ to ‘”a Neutral”‘ outlook in a report released in mid May. As of December 10, 2024, JMP Securities has initiated its “Mkt outperform” rating for PRME. Earlier on May 20, 2024, H.C. Wainwright initiated its rating. Their recommendation was “a Buy” for PRME stock.
Analyzing PRME Stock Performance
During the last five days, there has been a drop of approximately -2.38%. Over the course of the year, Prime Medicine Inc shares have dropped approximately -57.88%. Shares of the company reached a 52-week high of $3.5900 on 01/06/25 and a 52-week low of $1.1100 on 05/22/25.
Support And Resistance Levels for Prime Medicine Inc (PRME)
According to the 24-hour chart, there is a support level at 1.1417, which, if violated, would cause prices to drop to 1.0533. In the upper region, resistance lies at 1.2867. The next price resistance is at 1.3433. RSI (Relative Strength Index) is 42.53 on the 14-day chart, showing neutral technical sentiment.
